Moreover, PECAM-1 could be considered as a potential therapeutic target for protecting the CNS from the cytotoxicity exerted by the immune cells and preventing the sustained cognitive impairment observed in conjunction with brain atrophy, even later than 6 months after surgery [28,29]. This evidence concerns the gene PECAM1 and Cognitive impairment.